Disease relevance of Uveitis, Intermediate

• The day-time MEL was reduced significantly (P < or = 0.01) in patients with iritis and iridocyclitis, and highly significantly (P < or = 0.001) in patients with intermediate uveitis, chorioretinitis and panuveitis [1].
• A patient with chronic cyclitis developed hyperemia of the episcleral and bulbar conjunctival vessels after retrobulbar injections of methylprednisolone acetate suspension [2].
• METHODS: Interleukin 8 (IL-8) and C reactive protein (CRP) serum levels were measured in patients with idiopathic intermediate uveitis (n = 61), uveitis controls (n = 143), and normal controls (n = 29) [3].
• Eighteen patients with severe, progressive nonmicrobial inflammatory ophthalmic disease (including five with intermediate uveitis, four with sympathetic ophthalmia and three with serpiginous choroiditis) that had not responded to conventional therapy were treated with cyclosporine [4].
• In addition to decreased ERG amplitudes a delay of implicit time may be an important sign of pathology, i.e. the pronounced delay of implicit times in the periphery in retinitis pigmentosa and the implicit time delays in regions associated with retinal edema like CRVO and cystoid macula edema in intermediate uveitis [5].

High impact information on Uveitis, Intermediate

• Fluorescein angiography of the iris and specular microscopy of the corneal endothelium in some cases of glaucoma secondary to chronic cyclitis [6].
• Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis [7].
• The use of low dose methotrexate in children with chronic anterior and intermediate uveitis [8].
• RESULTS: Control of the intermediate uveitis required sustained doses of topical and periocular corticosteroids as well as systemic cyclosporine [9].
• AIM: To investigate peripheral blood lymphocyte phenotype in patients with intermediate uveitis using CD69, chemokine receptor, and cytokine expression [10].

Chemical compound and disease context of Uveitis, Intermediate

• The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis [11].
• Five patients with pure ocular localisation had initially received steroid treatment for intermediate uveitis [12].
• We report a case of successful management of iatrogenic intravitreal triamcinolone acetonide for intermediate uveitis [13].

Anatomical context of Uveitis, Intermediate

• CONCLUSION: No autoantibodies against the HNK-1 epitope or other antigens of the ciliary body could be demonstrated in patients with intermediate uveitis [14].

Gene context of Uveitis, Intermediate

• PRL was significantly reduced (P < 0.01) in patients with intermediate uveitis [1].
• Increased levels of sICAM-1 correlated with interleukin 8 levels (IL-8) (tested in a previous study in the same group of intermediate uveitis patients) in patients with active systemic involvement [15].
• Soluble ICAM-1 serum levels in patients with intermediate uveitis [15].
• A total of 52 nonrelated Caucasian patients (21 male, 31 female, age at onset of the disease: 7-74 years, average: 31.6 years) suffering from intermediate uveitis were tissue typed for 56 different HLA-A, -B, -C and -DR-antigens [16].
• The serum interleukin-2 receptor levels of patients with ocular Behçet's disease were significantly different from the levels of both the control and the intermediate uveitis groups (P < .001) [17].

Analytical, diagnostic and therapeutic context of Uveitis, Intermediate

• The mean serum interleukin-2 receptor level was 412.6 +/- 94.6 U/ml for the control group, 465.0 +/- 96.6 U/ml for the patients with intermediate uveitis, and 810.9 +/- 369.3 U/ml for those with ocular Behçet's disease [17].
• METHOD: Serum concentrations of soluble interleukin-2 receptor alpha (IL-2 s Ralpha) and soluble tumor necrosis factor receptor-1 (sTNF-R1) were measured in patients with intermediate uveitis (n = 26), posterior uveitis (n = 23) and healthy controls (n = 12) using ELISA [18].

References